Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-01-01
2008-01-01
Duffy, Patricia A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S023700
Reexamination Certificate
active
10746251
ABSTRACT:
The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain ofChlamydia, specificallyC. pneumoniae, employing a vector containing a nucleotide sequence encoding OMP (outer membrane protein) of a strain ofChlamydia pneumoniaeand a promoter to effect expression of the OMP (outer membrane protein) gene in the host. Modifications are possible within the scope of this invention.
REFERENCES:
patent: 6521745 (2003-02-01), Murdin et al.
patent: 6559294 (2003-05-01), Griffais et al.
patent: 6693087 (2004-02-01), Murdin et al.
patent: 6808713 (2004-10-01), Murdin et al.
patent: 6822071 (2004-11-01), Stephens et al.
patent: 7019125 (2006-03-01), Murdin et al.
patent: 7070792 (2006-07-01), Murdin et al.
patent: 7081245 (2006-07-01), Murdin et al.
patent: 2002/0082402 (2002-06-01), Murdin et al.
patent: 2002/0094340 (2002-07-01), Murdin et al.
patent: 2002/0094965 (2002-07-01), Murdin et al.
patent: 2002/0099188 (2002-07-01), Murdin et al.
patent: 2002/0132994 (2002-09-01), Murdin et al.
patent: 2003/0100706 (2003-05-01), Murdin et al.
patent: 2004/0254130 (2004-12-01), Murdin et al.
patent: WO 98/02546 (1998-01-01), None
patent: WO 98/58953 (1998-12-01), None
patent: WO 99/27105 (1999-06-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO 00/24765 (2000-05-01), None
patent: WO00/27994 (2000-05-01), None
patent: WO 00/34483 (2000-06-01), None
patent: WO 00/37494 (2000-06-01), None
patent: WO 00/46359 (2000-08-01), None
patent: WO 00/66739 (2000-11-01), None
patent: WO 01/21804 (2001-03-01), None
patent: WO 01/21811 (2001-03-01), None
patent: WO 01/40474 (2001-06-01), None
patent: WO 01/46224 (2001-06-01), None
patent: WO 01/81379 (2001-11-01), None
patent: WO 01/85972 (2001-11-01), None
patent: WO 02/02606 (2002-01-01), None
patent: WO 02/08267 (2002-01-01), None
Houghten et al. (New Approaches to Immunization, Vaccines86, Cold Spring Harbor Laboratory, p. 21-25, 1986.
Lederman et al. (Molecular Immunology 28: 1171-1181, 1991).
Li et al. (PNAS 77: 3211-3214, 1980).
Harlow et al , Antibodies, A Laboratory Manual, Cold Spring Harbor Press, Inc. 1988, p. 72.
The Dictionary of Immunology, Herbert et al eds, Academic Press, p. 187.
Feng et al (Infection and Immunity 64(1):363-365, 1996.
Grayston, J. Thomas et al., “Evidence thatChlamydia pneumoniaeCauses Pneumonia and Bronchitis”,The Journal of Infectious Diseases, The University of Chicago Press, vol. 168, No. 5, pp. 1231-1235, (Nov. 1993).
Campos, Mauro et al., “A Chlamydial Major Outer Membrane Protein Extract as a Trachoma Vaccine Candidate”,Investigative Ophthalmology&Visual Science, Association for Research in Vision and Ophthalmology, vol. 36, No. 8, pp. 1477-1491, (Jul. 1995).
Grayston, J. Thomas et al., “A New Respiratory Tract Pathogen;Chlamydia pneumoniaeStrain TWAR”,The Journal of Infectious Diseases, The University of Chicago Press, vol. 161, No. 4, pp. 618-625, (Apr. 1990).
Marrie, T. J., “Community-Acquired Pneumonia”,Clinical Infectious Diseases, The University of Chicago Press, vol. 18, No. 4, pp. 501-669, (Apr. 1994).
Wang, S.P. et al., “Chlyamydia Infections”,Microimmunofluorescence Serological Studies with the TWAROrganism, Cambridge Unviersity Press, pp. 329-333, (Jun. 1986).
Saikku, P. et al., “Serological Evidence of an Association of a Novel Chlyamydia, TWAR, with Chronic Coronary Heart Disease and Acute Myocardial Infarction”,The Lancet, vol. II, No. 8618, The Lancet Ltd., pp. 983-985, (Oct. 29, 1988).
Thom, David H. et al., “Association of Prior Infection withChlamydia pneumoniaeand Angiographicallly Demonstrated Coronary Artery Disease”,The Journal of the American Medical Association, vol. 268, No. 1,Chlamydia pneumoniaeand Coronary Artery Disease, pp. 68-72, (Jul. 1, 1992).
Linnanmaki, Eila et al., “Chlamydia pneumoniae-Specific Circulating Immune Complexes in Patients with Chronic Coronary Heart Disease”,Circulation, vol. 87, No. 4, pp. 1030-1134, (Apr. 1993).
Saikku, Pekka et al., “ChronicChlamydia pneumoniaeInfection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study”,Annals of Internal Medicine, vol. 116, No. 4, American College of Physicians, pp. 273-278, (Feb. 15, 1992).
Melnick, Sandra L.et al., “Past Infection byChlamydia pneumoniaeStrain TWAR and Asymptomatic Carotid Atherosclerosis”,The American Journal of Medicine, vol. 95, pp. 499-504, (Nov. 1993).
Shor, A. et al., “Detection ofChlamydia pneumoniaein coronary arterial fatty streaks and atheromatous plaques”,South African Medical Journal, vol. 82, National Center for Occupational Health, pp. 158-161, (Sep. 1992).
Kuo, Cho-chou et al., “Demonstration ofChlamydia pneumoniaein Atherosclerotic Lesions of Coronary Arteries”,The Journal of Infectious Diseases, vol. 167, No. 4, The University of Chicago, pp. 841-849, (Apr. 1993).
Kuo, Cho-chou et al., “Dection ofChlamydia pneumoniaein Aortic Lesions of Atherosclerosis by Immunocytochemical Stain”,Arterosclerosis and Thrombosis, vol. 13, No. 10, pp. 1501-1504, (Oct. 1993).
Campbell, Lee Ann et al., “Detection ofChlamydia pneumoniaeTWAR in Human Coronary Atherectomy Tissues”,The Journal of Infectious Diseases, vol. 172, The University of Chicago, pp. 585-588, (Aug. 1995).
Chiu, B. et al., “Chlamydia pneumoniae, Cytomegalovirus, and Herpes Simplex Virus in Atherosclerosis of the Carotid Artery”,Circulation, vol. 96, No. 7, American Heart Association, pp. 2144-2148, (Oct. 7, 1997).
Ramirez, Julio A. et al., “Isolation ofChlamydia pneumoniaefrom the Coronary Artery of a Atherosclerosis”,Annals of Internal Medicine, vol. 125, No. 12, American College of Physicians, pp. 979-982, (Dec. 15, 1996).
Jackson, Lisa A. et al., “Isolation ofChlamydia pneumoniae(TWAR) from a carotid atherosclerotic plaque specimen obtained by endarterectomy”,Abstracts of the 36th ICAAC, p. 272, (Sep. 1996).
Fong, Ignatius W. et al., “Rabbit Model forChlamydia pneumoniaeInfection”,Journal of Clinical Microbiology, vol. 35, No. 1, American Society of Microbiology, pp. 48-52, (Jan. 1997).
Hahn D.L. et al., “Evidence forChlamydia pneumoniaeinfection in steriod-dependent asthma”,Annals of Allergy Asthma, &Immunology., vol. 80, No. 1, pp. 45-49, Jan. 1998.
Hahn, D.L. et al., “Association ofChlamydia pneumoniaeIgA antibodies with recently simptomatic asthma”,Epidemiology Infection, vol. 117, No. 3, Cambridge University Press, pp. 513-517, (Dec. 1996).
Bjornsson Eythor, et al., “Serology of Chlamydia in Relation to Asthma and Bronchial Hyperresponsiveness”,Scand J Infect. Dis., vol. 28, No. 1, Scandinavian University Press, pp. 63-69, (1996).
Hahn D.L. “Treatment ofChlamydia pneumoniaeInfection in Adult Asthma: A Before-After Trial”,The Journal of Family Practice, vol. 41, No. 4, Appleton & Lange, pp. 345-351, (Oct. 1995).
Allegra L. et al., “Acute exacerbations of asthma in adults: role ofChlamydia pneumoniaeinfection”,Eur Respir J., vol. 7, No. 12, ERS Journals Ltd., pp. 2165-2168, (Dec. 1994).
Hahn D.L. et al., “Association ofChlamydia pneumoniae(Strain TWAR) Infection with Wheezing, Asthmatic Bronchitis, and Adult-Onset Asthma”,The Journal of the American Medical Association, vol. 266, No. 2, pp. 225-230, (Jul. 10, 1991).
Pal Sukumar et al., “Intranasal Immunization Induces Long-Term Protection in Mice against aChlamydia trachomatisGenital Challenge”,Infection and Immunity, vol. 64, No. 12, American Society of Microbiology,.pp. 5341-5348, (Dec. 1996).
Jones, Gareth E. et al., “Efficacy trials with tissue-culture grown, inactivated vaccines against chlamydial abortion in sheep”,Vaccine, vol. 13, No. 8, Elsevier Science, Ltd., pp. 715-723, (1995).
Igietseme, Joseph U. et al., “Resolution of Murine Chlamydial Genital Infection by the Adoptive T
Dunn Pamela
Murdin Andrew D.
Oomen Raymond P.
Wang Joe
Duffy Patricia A.
Sanofi Pasteur Limited
LandOfFree
Chlamydia antigens and corresponding DNA fragments and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chlamydia antigens and corresponding DNA fragments and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlamydia antigens and corresponding DNA fragments and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3933173